logo

Vertex Pharmaceuticals Inc. (VRTX)



Trade VRTX now with
  Date
  Headline
5/5/2022 4:26:21 PM Vertex Pharma Q1 EPS $2.96 Vs. $2.49 Year Ago
5/2/2022 8:34:56 AM Vertex Updates On Phase 1/2 Clinical Trial Of VX-880 For Treatment Of Type 1 Diabetes
3/25/2022 8:02:49 AM Vertex :Canada Grants Marketing Authorization For KALYDECO For Patients With Cystic Fibrosis Ages Of 4 Months -18 Yrs
3/22/2022 8:07:18 AM Vertex Advances VX-147 Into Pivotal Clinical Development For People With APOL1-Mediated Kidney Disease
1/26/2022 4:55:40 PM Vertex Pharma Q4 EPS $3.00 Vs. $2.30 Last Year
1/11/2022 3:06:38 AM Vertex Pharma: EU Approves KAFTRIO In Combination With Ivacaftor For Cystic Fibrosis In Patients Ages 6 Through 11 Years
12/1/2021 7:38:38 AM Vertex Announces Positive Results From Phase 2 Study Of VX-147 In APOL1-Mediated FSGS
11/19/2021 6:03:35 AM Vertex Announces Reimbursement Deal In Spain For KAFTRIO In Combination With Ivacaftor To Treat Cystic Fibrosis